PTC Therapeutics (PTCT) concentration risks

The company's concentration profile is defined by two marketed products, each carrying a moderate disclosed share and structural character — though each faces a distinct commercial risk. The first, Translarna, carries a risk that a significant portion of the company's ability to generate revenue from sales in the European Economic Area could be lost. This dependency on a single geography-specific regulatory authorization means that EEA revenue from Translarna is exposed to access decisions and reimbursement negotiations that can shift independently of the product's clinical performance. The second product, Emflaza, faces competitive pressure from generics that has already had a negative impact on net product revenue and is expected to continue doing so. This is a structural risk inherent to the branded pharmaceutical life cycle: once generics enter, price and volume pressure tends to compound over time. The ongoing erosion is disclosed rather than prospective, indicating that the revenue contribution from Emflaza is already declining. Taken together, the two-product revenue base creates a profile where each asset faces a distinct but material challenge: one is subject to EEA regulatory and reimbursement uncertainty, the other is facing generic competition. Neither exposure is idiosyncratic in the sense of a single counterparty dependency, but both share the characteristic that the path to stabilizing or growing revenues from each product faces headwinds that are largely outside the company's control. There are no disclosed geographic, customer, or supplier concentrations layered on top of the product profile.

For the engine’s reasoning on PTCT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.